Progressive repigmentation of hypopigmented lesions in discoid lupus erythematosus with anifrolumab: A report of two cases.

We report two cases of patients with refractory discoid lupus erythematosus (DLE) and dark skin phototypes who experienced progressive perifollicular repigmentation of depigmented lesions under anifrolumab therapy, with sustained improvement over 18 months. These observations highlight a potential novel effect of anifrolumab on cicatricial dyspigmentation in DLE. This effect may represent a valuable therapeutic option for DLE-related damage, particularly in patients with darker skin types.

Methotrexate as a corticosteroid-sparing agent in leprosy reactions: A French multicenter retrospective study.

Introduction: Leprosy reactions (LRs) are inflammatory responses observed in 30%-50% of people with leprosy. First-line treatment is glucocorticoids (GCs), often administered at high doses with prolonged courses, resulting in high morbi-mortality. Methotrexate (MTX) is an immunomodulating agent used to treat inflammatory diseases and has an excellent safety profile and worldwide availability.